China NRDL 2026: Pfizer and Innovent GLP-1s Win Coverage as 107 Drugs Join
China’s 2026 reimbursement list adds 107 drugs, including Pfizer’s ecnoglutide and Innovent’s mazdutide for diabetes, from 1 January 2027.
China’s 2026 reimbursement list adds 107 drugs, including Pfizer’s ecnoglutide and Innovent’s mazdutide for diabetes, from 1 January 2027.